{
  "symbol": "ABVC",
  "company_name": "Abvc Biopharma Inc",
  "ir_website": "https://abvcpharma.com/?page_id=16826",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "PRESS RELEASES Latest News",
          "url": "https://abvcpharma.com/?page_id=17318",
          "content": "  * [](#grve-search-modal)\n\n\n\n[ ![ABVC BioPharma, Inc.](//abvcpharma.com/wp-content/uploads/2021/03/abvcstickylogo300x100.png) ](https://abvcpharma.com/)\n\n[ ](#grve-hidden-menu)\n\n# News\n\nNASDAQ: ABVC\n\n### Press Releases\n\n## [ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones](https://abvcpharma.com/?p=17794) ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 Press Release Press Release https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g November 14, 2024 November 17, 2024\n\n  * Press Release\n  * November 14, 2024 \n\n\n\nABVC BioPharma, Inc. Reports Q3 ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in income Received Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024 FREMONT, Calif., Nov. 14, 2024 — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the third quarter ended September 30, 2024. Key Financial and Operational Highlights:…\n\n## [Indian Talent in Taiwan](https://abvcpharma.com/?p=17761) Indian Talent in Taiwan https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 ABVC ABVC https://secure.gravatar.com/avatar/fca8810fafc48ff205f8de427ddbfd02?s=96&d=mm&r=g August 28, 2024 August 28, 2024\n\n  * August 28, 2024 \n\n\n\nLots of Indians work and study in Taiwan! Dr. Priya is visiting some students and professionals currently working in Taiwan to see how they feel about their lives here. This episode highlights ABVC’s CEO Uttam Patil and some of our hardworking colleagues in our Taiwan office. https://www.youtube.com/watch?v=xLBStpD5BAI\n\n## [ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements](https://abvcpharma.com/?p=17754) ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 Press Release Press Release https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g August 15, 2024 August 15, 2024\n\n  * August 15, 2024 \n\n\n\n• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1. Significant Global Licensing Agreements: – Vitargus® Licensing: Along with our subsidiary, BioFirst Corporation, we secured licensing agreements with ForSeeCon Eye…\n\n## [All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504](https://abvcpharma.com/?p=17749) All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504 https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 ABVC ABVC https://secure.gravatar.com/avatar/fca8810fafc48ff205f8de427ddbfd02?s=96&d=mm&r=g July 10, 2024 July 10, 2024\n\n  * July 10, 2024 \n\n\n\n## [ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI](https://abvcpharma.com/?p=17747) ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 Press Release Press Release https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g July 9, 2024 July 9, 2024\n\n  * July 9, 2024 \n\n\n\nFREMONT, CA – July 9, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II clinical trials of their medication to treat Major Depressive Disorder (MDD), the Company and AiBtl BioPharma Inc. are working towards a new clinical study on Depression in Cancer Patients by integrating AI-driven solutions. Depression is a significant concern among cancer patients, often complicating treatment and affecting the overall quality of life.[1] “This study aims to understand better the prevalence and impact of depression in this vulnerable population and to explore…\n\n### 2024 ABVC Investor Presentation\n\nView the latest product information, status updates, financial information, and more.\n\n[VIEW PRESENTATION](https://abvcpharma.com/wp-content/uploads/2024/08/ABVC-Corporate-Overview-Summer-2024.pdf \"View Presentation PDF \\(opens in new window\\)\")\n\n[PRESS RELEASES](https://www.globenewswire.com/search/keyword/abvc?pageSize=10 \"Press Releases\")\n\n[SEC FILINGS](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001173313&owner=exclude&count=40)\n\n[INVESTOR CONSIDERATIONS](#abvc-investors)\n\n[CONTACT ABVC](#abvc-contact)\n\n##### SAFE HARBOR STATEMENT\n\nWith the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.\n\n## Investor Considerations\n\n  * Strong portfolio of medicines and medical devices addresses wide range of disorders.\n  * In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.\n  * MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.\n  * Botanical expertise leads to medicines with fewer side effects.\n  * Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.\n  * Business model designed to minimize burn rate.\n  * Less than 30 million shares outstanding.\n\n\n\n![](https://abvcpharma.com/wp-content/uploads/2020/03/abvc_block02-150x40.png)\n\nEnter yoursearch terms here.\n\nLogin to ABVC BioPharma, Inc.\n\nLogin [Lost Password?](#)\n\nReset Password\n\nEnter the username or e-mail you used in your profile. A password reset link will be sent to you by email.\n\nGet new password\n\nAlready have an account? [Login](#)\n"
        }
      ]
    },
    {
      "section_name": "Investor Considerations",
      "links": [
        {
          "title": "NEW: Summer 2023 Investor Presentation",
          "url": "https://abvcpharma.com/wp-content/uploads/2023/06/ABVC-Corporate-Overview-Summer-2023.pdf",
          "content": "Error extracting PDF content: 406 Client Error: Not Acceptable for url: https://abvcpharma.com/wp-content/uploads/2023/06/ABVC-Corporate-Overview-Summer-2023.pdf"
        }
      ]
    }
  ]
}